TiGenix purchased by Takeda

Date: January 16, 2018

Takeda Pharmaceutical Co has announced that it has acquired TiGenix N.V. for €520m (£460m). Takeda and TiGenix have an existing partnership for Alofisel (or darvadstrocel, Cx601) an allogeneic expanded adipose derived stem cell therapy for the treatment of complex perianal fistulas in patients with luminal Crohn’s disease. Takeda was granted exclusive rights to the therapy the outside of the US by TiGenix in 2016 and European approval is expected later this year. TiGenix has technology platforms based on allogeneic adipose-derived stem cells and allogeneic cardiac stem cells.

Back to News Overview